Rise and shine, everyone, another busy day is on the way. We can tell because the short person made another last-minute dash for the local schoolhouse and a parade of vehicles has passed by the placid Pharmalot campus in a hurry. As for us, we are contemplating such frantic paces with a cup of stimulation — peppermint mocha is the choice today. Perhaps this will inspire you to find one of your own. Meanwhile, time to get cracking. Here are a few tidbits to help you on your journey today. Best of luck, and do keep in touch.

Pete Buttigieg has said he wants drug companies to “thrive,” but thriving under a Buttigieg administration will not be business as usual for the pharmaceutical industry, STAT explains. The former mayor of South Bend, Ind., has an expansive platform to lower drug prices that relies on aggressive planks including Medicare negotiation and, if need be, stripping monopolies from companies determined to have priced their drugs abusively.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy